Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Open-angle Glaucoma (POAG) Clear all
Completed Phase 2 Interventional Results available

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

NCT03216902
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 24, 2026, 7:56 AM EDT
Completed No phase listed Observational Results available

PRESERFLO® MicroShunt Extension Study

NCT04333433
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
PRESERFLO® MicroShunt, Trabeculectomy
Device · Procedure
Lead sponsor
InnFocus Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
279 participants
Timeline
2020 – 2022
U.S. locations
19
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years to 99 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Goose Creek, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 24, 2026, 7:56 AM EDT
Completed No phase listed Observational

Pigment Dispersion Syndrome With and Without Glaucoma

NCT00001152
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1976 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 7:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Efficacy of Selective Laser Trabeculoplasty

NCT00347893
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension, Pseudo-Exfoliative Glaucoma, Pigment Dispersion Glaucoma
Interventions
Selective laser trabeculoplasty
Procedure
Lead sponsor
Glaucoma Research & Education Group
Other
Eligibility
0 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

NCT01560975
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 24, 2026, 7:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

NCT04396002
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Completed No phase listed Observational Results available

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

NCT01836042
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 24, 2026, 7:56 AM EDT
Terminated Not applicable Interventional

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

NCT04769453
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro
Device
Lead sponsor
Nova Eye, Inc.
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Jul 24, 2026, 7:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?

NCT00626847
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 1Phase 2 Interventional

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

NCT01654484
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 24, 2026, 7:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Innovations in Glaucoma Study

NCT00221897
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Myopia
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Active, not recruiting No phase listed Observational

A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma

NCT06615661
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG)
Interventions
C-Rex Instrument
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
22 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Cape Coral, Florida • DeLand, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 24, 2026, 7:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

NCT03675412
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
Caffeine tablet
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Terminated Phase 4 Interventional

A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

NCT06407973
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
45 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Petaluma, California • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Terminated No phase listed Observational

Development and Validation of a Model to Predict Fast Progression in Glaucoma

NCT04454190
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions
Collection of genetic material
Diagnostic Test
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
1,152 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Jul 24, 2026, 7:56 AM EDT
Terminated Not applicable Interventional

Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

NCT04784234
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

NCT02036541
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
AqueSys XEN 45 Glaucoma Implant
Device
Lead sponsor
AqueSys, Inc.
Industry
Eligibility
45 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jul 24, 2026, 7:56 AM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

NCT02928289
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 24, 2026, 7:56 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

NCT01336569
View directory record Official record
Conditions
Glaucoma
Interventions
Travoprost 0.004%/timolol maleate 0.5% fixed combination
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Jul 24, 2026, 7:56 AM EDT